{
    "clinical_study": {
        "@rank": "20103", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Etanercept", 
                "arm_group_type": "Experimental", 
                "description": "Patient will receive 0.4 mg/kg of Etanercept subcutaneously twice weekly."
            }
        ], 
        "brief_summary": {
            "textblock": "Studying the effects of Etanercept (an anti-TNF alpha) on early CRPS.  Our hypothesis is\n      that Etanercept will improve patient symptoms if given in early CRPS."
        }, 
        "brief_title": "Etanercept for the Treatment of CRPS", 
        "condition": [
            "CRPS", 
            "Chronic Regional Pain Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": "Complex Regional Pain Syndromes"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Female pediatric CRPS patients with unilateral CRPS of the lower extremity, ages\n             10-17 years of age.\n\n          2. Patients must meet CRPS Type I diagnostic criteria and have current evidence of\n             edema, and a temperature difference between the affected and contralateral limb\n             \u22651.0\u00b0C.\n\n          3. Duration of symptoms less than 4 months.\n\n        Exclusion Criteria:\n\n          1. Active malignancy or history of malignancy.\n\n          2. Active infection.\n\n          3. History of TB or TB exposure.\n\n          4. Pregnancy.\n\n          5. Concomitant disease causing immunocompromise.\n\n          6. Concomitant autoimmune disease such as rheumatoid arthritis, psoriasis, ankylosing\n             spondylitis or Crohn's Disease.\n\n          7. Poorly controlled psychiatric disease including anxiety, depression or ADHD.\n\n          8. Hepatic or renal impairment as indicated by serum transaminases and/or creatinine \u2265\n             150% normal value for age.\n\n          9. Evidence of or history of demyelinating disease."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031211", 
            "org_study_id": "29290"
        }, 
        "intervention": {
            "arm_group_label": "Etanercept", 
            "intervention_name": "Etanercept", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "TNFR-Fc fusion protein"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2014", 
        "number_of_arms": "2", 
        "official_title": "Etanercept for the Treatment of CRPS", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The participant will keep a daily record of their pain via the Visual Analog Score.", 
            "measure": "Visual Analog Scale", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031211"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}